Analysts expect that Dicerna Pharmaceuticals (NASDAQ:DRNA) will post ($0.30) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.30). Dicerna Pharmaceuticals posted earnings of ($0.68) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 55.9%. The business is expected to report its next earnings report on Monday, May 14th.

Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.25). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The company’s revenue was up 976.9% compared to the same quarter last year.

DRNA has been the subject of a number of recent research reports. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. SunTrust Banks initiated coverage on shares of Dicerna Pharmaceuticals in a report on Monday, February 5th. They issued a “buy” rating and a $13.00 target price for the company. Stifel Nicolaus boosted their target price on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, March 9th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 12th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $12.54.

Hedge funds have recently modified their holdings of the company. Endurant Capital Management LP purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth about $170,000. Emerald Advisers Inc. PA purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth about $266,000. Northern Trust Corp grew its stake in shares of Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the fourth quarter worth about $581,000. Finally, Millennium Management LLC grew its stake in shares of Dicerna Pharmaceuticals by 142.8% during the fourth quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 39,348 shares during the last quarter. Institutional investors and hedge funds own 75.32% of the company’s stock.

Dicerna Pharmaceuticals stock traded down $0.78 during trading hours on Monday, reaching $11.23. The stock had a trading volume of 1,774,476 shares, compared to its average volume of 531,566. The company has a market capitalization of $621.72, a PE ratio of -3.07 and a beta of 2.34. Dicerna Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $15.00.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/04/23/0-30-eps-expected-for-dicerna-pharmaceuticals-drna-this-quarter.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.